Abstract
Recent studies have suggested that in patients with an idiopathic interstitial pneumonia (IIP), a probable usual interstitial pneumonia (UIP) pattern on chest computed tomography (CT) is sufficient to diagnose idiopathic pulmonary fibrosis (IPF) without histopathology.
We retrospectively compared the prognosis and time to first acute exacerbation (AE) in IIP patients with a UIP and a probable UIP pattern on initial chest CT.
One hundred and sixty IIP patients with a UIP pattern and 242 with a probable UIP pattern were identified. Probable UIP pattern was independently associated with longer survival time (adjusted hazard ratio 0.713, 95% CI 0.536–0.950; p=0.021) and time to first AE (adjusted hazard ratio 0.580, 95% CI 0.389–0.866; p=0.008). In subjects with a probable UIP pattern who underwent surgical lung biopsy, the probability of a histopathological UIP pattern was 83%. After multidisciplinary discussion and the inclusion of longitudinal behaviour, a diagnosis of IPF was made in 66% of cases. In IPF patients, survival time and time to first AE were not associated with CT pattern. Among subjects with a probable UIP pattern, compared to non-IPF patients, survival time and time to first AE were shorter in IPF patients.
In conclusion, IIP patients with a probable UIP pattern on initial chest CT had a better prognosis and longer time to first AE than those with a UIP pattern. However, when baseline data and longitudinal behaviour provided a final diagnosis of IPF, CT pattern was not associated with these outcomes. This suggests diagnostic heterogeneity among patients with a probable UIP pattern.
Abstract
Except when the final diagnosis is IPF, idiopathic interstitial pneumonia (IIP) patients with a probable usual interstitial pneumonia (UIP) pattern on chest CT have a longer survival time and time to first acute exacerbation than those with a UIP pattern http://bit.ly/2FOJa2F
Footnotes
This article has an editorial commentary: https://doi.org/13993003.00590-2020
This article has supplementary material available from erj.ersjournals.com
Conflict of interest: J. Fukihara has nothing to disclose.
Conflict of interest: Y. Kondoh has nothing to disclose.
Conflict of interest: K.K. Brown has nothing to disclose.
Conflict of interest: T. Kimura has nothing to disclose.
Conflict of interest: K. Kataoka has nothing to disclose.
Conflict of interest: T. Matsuda has nothing to disclose.
Conflict of interest: Y. Yamano has nothing to disclose.
Conflict of interest: A. Suzuki has nothing to disclose.
Conflict of interest: T. Furukawa has nothing to disclose.
Conflict of interest: H. Sumikawa has nothing to disclose.
Conflict of interest: O. Takahashi has nothing to disclose.
Conflict of interest: T. Johkoh has nothing to disclose.
Conflict of interest: T. Tanaka has nothing to disclose.
Conflict of interest: J. Fukuoka has nothing to disclose.
Conflict of interest: N. Hashimoto has nothing to disclose.
Conflict of interest: Y. Hasegawa has nothing to disclose.
Support statement: This work was supported in part by a grant-in-aid for the interstitial lung disease research group from the Japanese Ministry of Health, Labour and Welfare (H29-023). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received December 29, 2018.
- Accepted December 31, 2019.
- Copyright ©ERS 2020